Companies · Biotech / Pharma

Cornovus Pharmaceuticals Inc.

FARMINGTON · Biotech / Pharma · refined from filed group “Other

Diligence memoA one-page analyst read on Cornovus Pharmaceuticals Inc. — recommendation, valuation, rhythm, risks.
$3.1M
Total raised · real
3
Rounds
0.5×
Latest step-up
Top 59%
Sector rank · raised
Seed
Latest stage · inferred · Mon Jan 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Cornovus Pharmaceuticals Inc. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.18× the median modeled value of Seed Biotech / Pharma companies in 2022–2024 (14 peers) — value vs value, same stage and era.
Quiet
  • Last raise 2.4 yr ago; this sector typically re-raises about every 15 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Cornovus Pharmaceuticals Inc. is one of 227 Biotech / Pharma companies tracked from FARMINGTON. By capital raised it ranks mid-pack (ahead of 42% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(c)
Reg D exemption
1
Investors (latest)
2024-01-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2014-02-28 Raised $1.6M (real) Modeled valuation $65M (est)$1.6M$65MSeed2014Seed · 2016-08-10 Raised $983K (real) Modeled valuation $40M (est)$983K$40MSeed2016Seed · 2024-01-22 Raised $500K (real) Modeled valuation $3.0M (est)$500K$3.0MSeed2024+$983K+$500KCumulative $3.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.6M · 2014
Seed extension$983K · 2016
Seed extension$500K · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$3.0M
Base estimate est.
$369K
Conservative case
$9.1M
Upside case
$2.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Seed · modeled $65.5M · 2014-02-282014Seed · modeled $40.4M · 2016-08-10Seed · modeled $3.0M · 2024-01-222024
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
33%
Survival probability
15% low · 51% high
1.71×/yr
Annual markup
2.24×/yr upside case
2.4 yr
Elapsed time used
2.4 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
59 mo
Avg between rounds
$311K/yr
Capital velocity
12.3 yr
On record since
2014
First round
3
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.5× of median
This company$3.1M
Sector median$5.6M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.3× of median
This company$500K
Sector median$1.9M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$3.0M
Sector median$30.5M

Raised more than 42% of sector peers (real $). Modeled value above 20% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #12 of 14.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0MCapital raised (log)Outer Biosciences, LLC · Seed Raised $4.0M · modeled $66.1M (est)Slate Bio, Inc. · Seed Raised $4.8M · modeled $29.9M (est)CASS Pharmaceuticals, Inc. · Seed Raised $2.1M · modeled $26.0M (est)FOOP Organic Biosciences, Inc. · Seed Raised $2.0M · modeled $25.8M (est)Trio Pharmaceuticals, Inc. · Seed Raised $1.9M · modeled $22.5M (est)Aruka Bio, Inc. · Seed Raised $3.5M · modeled $19.0M (est)Yatiri Bio, Inc. · Seed Raised $2.9M · modeled $18.1M (est)Galatea Bio, Inc. · Seed Raised $3.7M · modeled $16.2M (est)Sedare Biosciences, Inc. · Seed Raised $2.5M · modeled $15.5M (est)Klothea Bio, Inc. · Seed Raised $2.9M · modeled $12.1M (est)IdentifySensors Biologics Corp. · Seed Raised $2.1M · modeled $8.0M (est)Cornovus Pharmaceuticals Inc. (this company) Raised $3.1M · modeled $3.0M (est)Cornovus Pharmaceuticals Inc.
CompanyStageRaised · realValue · estvs peer med.
Outer Biosciences, LLCSeed$4.0M$66.1M3.85×
Slate Bio, Inc.Seed$4.8M$29.9M1.74×
CASS Pharmaceuticals, Inc.Seed$2.1M$26.0M1.51×
FOOP Organic Biosciences, Inc.Seed$2.0M$25.8M1.50×
Trio Pharmaceuticals, Inc.Seed$1.9M$22.5M1.31×
Aruka Bio, Inc.Seed$3.5M$19.0M1.11×
Yatiri Bio, Inc.Seed$2.9M$18.1M1.05×
Galatea Bio, Inc.Seed$3.7M$16.2M0.95×
Sedare Biosciences, Inc.Seed$2.5M$15.5M0.90×
Klothea Bio, Inc.Seed$2.9M$12.1M0.71×
IdentifySensors Biologics Corp.Seed$2.1M$8.0M0.46×
Cornovus Pharmaceuticals Inc. this companySeed$3.1M$3.0M0.18×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.6M2014-02-28$8.0M$65.5M85%
Seed$983K2016-08-10$4.9M$40.4M85%
Seed$500K2024-01-22$2.5M$3.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.6M2014-02-28
    • First recorded raise — entered as Seed.
    • 1 investor on this round.
  2. Seed$983K2016-08-10
    • Raised again after 29 mo — slower than the ~15 mo sector norm.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  3. Seed$500K2024-01-22
    • Raised again after 89 mo — slower than the ~15 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • Switched to Rule 506(c) (was Rule 506(b)).
    • 1 investor on this round.
Intelligence
2029 ~Q1
Modeled next raise · ~59mo cadence
$500K
Modeled next size est.range $500K$800K
0.5×
Last step-up
$311K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Daniel Wagner12 other2016-08
Timothy Shannon8 other2016-08
R. Mark Van Allen1 other2024-01
Bruce Liang2016-08
Glenn Mattes2016-08
Raymond Neag2016-08
Robert Mark Van Allen2014-02
Registry & provenance

Cornovus Pharmaceuticals Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1600112
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Chirality Biosciences, Inc.Biotech / PharmaSeed$3.1M$7.4Msame sector · same stage
Klothea Bio, Inc.Biotech / PharmaSeed$2.9M$12.1Msame sector · same stage
Recreo Pharmaceuticals LlcBiotech / PharmaSeed$3.2M$123.4Msame sector · same stage
Yatiri Bio, Inc.Biotech / PharmaSeed$2.9M$18.1Msame sector · same stage
Catch Bio, Inc.Biotech / PharmaSeed$2.8M$1.5Msame sector · same stage
Aruka Bio, Inc.Biotech / PharmaSeed$3.5M$19.0Msame sector · same stage
Galatea Bio, Inc.Biotech / PharmaSeed$3.7M$16.2Msame sector · same stage
Massive Bio, Inc.Biotech / PharmaSeed$2.5M$104.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
PharmaCCX, Inc.Biotech / PharmaSeries A$45.1M82%
Key Biologics Holdings, LLCBiotech / PharmaSeries A$167.5M82%
PharmaCann Inc.Biotech / PharmaSeries D+$413.5M81%
AbX Biologics, Inc.Biotech / PharmaPre-Seed$51.2M81%
Manus Bio Inc.Biotech / PharmaSeries C$108.4M81%
INIA Biosciences, Inc.Biotech / PharmaPre-Seed$1.3M80%
CASS Pharmaceuticals, Inc.Biotech / PharmaSeed$26.0M80%
Empire Biotechnologies, Inc.Biotech / PharmaPre-Seed$5.6M80%
Frequently asked
How much funding has Cornovus Pharmaceuticals Inc. raised?
Cornovus Pharmaceuticals Inc. has raised approximately $3.1M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Cornovus Pharmaceuticals Inc.'s estimated valuation?
Provath's modeled valuation for Cornovus Pharmaceuticals Inc. is approximately $3.0M (modeled range $369K–$9.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cornovus Pharmaceuticals Inc. at?
Cornovus Pharmaceuticals Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Mon Jan 22.
What does Cornovus Pharmaceuticals Inc. do and where is it based?
Cornovus Pharmaceuticals Inc. operates in the Biotech / Pharma sector, based in FARMINGTON.
Explore related

See where Cornovus Pharmaceuticals Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cornovus Pharmaceuticals Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.